The University of Rochester Cancer Center (URCC) is a health and research institute organized as a multihospital consortium involving five full-service community hospitals. The URCC is committed to clinical and basic laboratory research, patient care, and education. All practicing oncologists in each of the five hospitals must, and do, hold at least two simultaneous primary appointments - one in the Cancer Center and one in a University department - and are subject to the policies and procedures of both the Center and the department. Performance sites also include our Canadian outreach satillite in Quebec City, Canada and a consortium CCOP facility in upstate NY. We are ideally suited to participate in the Eastern Cooperative Oncology Group treatment trials, cancer control studies, and other scientific research activities. Continued membership will enable us to bring the benefits of promising clinical investigations to the cancer community, accelerate the advances in cancer therapy, provide dissemination of information through rapid data collection and publications, and to improve the level of care and treatment to hopefully enhance the length of survival and quality of life in our cancer patients. Data and information from ECOG research projects are presented at regional, national and international meetings and conferences by the Rochester ECOG investigators. Important to this program is that the Cancer Center investigators and staff provide a strong link between laboratory research concepts, such as chemotherapy and radiation sensitizers and protectors, IL-2/LAK cell studies, chemoprevention studies, photo- dynamic therapy, tumor cell vaccine and lymphokine research. The URCC has a longstanding interest and experience in cancer control studies and will provide expertise to this expanded area of research within the ECOG. Key personnel are chairpersons or serve on steering committees of many of the ECOG modality, disease oriented and administrative committees. The URCC is the only cancer facility serving the Finger Lakes Health Region area, with a population of 1.2 million people.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA011083-26
Application #
3555966
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-06-01
Project End
1994-06-30
Budget Start
1993-05-01
Budget End
1994-06-30
Support Year
26
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Rimsza, Lisa M; Li, Hongli; Braziel, Rita M et al. (2018) Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. Haematologica 103:e151-e153
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Chen, Robert W; Li, Hongli; Bernstein, Steven H et al. (2017) RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 176:759-769

Showing the most recent 10 out of 222 publications